Business Wire

CA-ALTIUM-LLC

17.3.2021 09:32:08 CET | Business Wire | Press release

Share
Altium and AWS Collaborate to Advance Electronic Design

Altium LLC is committed to bringing transformation to the electronics industry through a digital platform that connects design to the supply chain and the manufacturing floor. To achieve this goal, Altium selected Amazon Web Services (AWS) to host Altium 365 , the cloud platform for collaborative PCB design and realization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005247/en/

The Altium 365 cloud-based platform and Altium Designer elevates PCB design by creating seamless collaboration points across the development process, making it the most connected design experience in the industry. This streamlines the product development process and allows engineers and designers to create smart and connected electronic products faster than ever before.

With Altium 365, users can bring together the stakeholders and participants in the electronic design process—even if they do not have Altium Designer—while keeping IPs secure and designs under control. Altium 365 provides a completely new way to share, visualize, and mark-up PCB designs for all stakeholders involved, from design managers to manufacturers, while allowing other designers to connect to the same PCB design with Altium Designer to author changes.

“AWS is central to Altium 365’s success to keep the platform, customers’ designs, and data secure, available and accessible,” said Greg Bellasis, Altium’s Director of Cybersecurity. “A broad portfolio of AWS services and the collaboration with their enterprise support team helps us achieve this goal to ensure ongoing stability, security, and reliability for our users to connect with anyone, from anywhere, in any time zone and from any web-enabled device to get their job done.”

Teams can organize designs, libraries, and participants in one place, and share links to their designs for easy, real-time collaboration. Designs are accessible at any time, on any device, anywhere, thanks to AWS’s proven global infrastructure. By leveraging CAD-specific intelligence, design data can be stored in a way that makes projects, files and version history accessible and easy to navigate on the web.

As Michael Weston, Lead Engineer in Kinetic Vision ’s Product Design and Development Group, explains, “We switched over to Altium 365 in January 2020 because we needed a more stable platform for our data and collaboration methods compared to the local methods we were using, but with the COVID-19 situation, the platform became even more essential because our team members could continue to work remotely. Altium 365 has given us more power to create brilliant work—no matter where our team is working from.”

“There’s a broad recognition that cloud is a more secure place to do collaborative projects than traditional on-premises infrastructures,” said David Pellerin, head of Worldwide Business Development for Infotech/Semiconductor at AWS. “By using the cloud to secure their most sensitive data and improve efficiencies and maximize collaboration, Altium and their customers can free up developers and engineers to focus on innovation.”

By combining the flexibility of sharing and collaboration in the cloud with the power of desktop PCB design software, Altium is making a big leap towards modernizing and transforming the way the electronics industry meets the growing demand for smart and connected products.

ABOUT ALTIUM

Altium LLC , a global software company headquartered in San Diego, California, is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

Social Media:

https://www.facebook.com/AltiumOfficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye